secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2022-07-11T23:59:59+00:00
Accession:  0001213900-22-038536
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity appoints three new directors, expands board from 4 to 6 members
------------------------------------------------------------------------

- Board size increased to 6; new directors: David Roth (independent), James Cullem (Interim CEO), Thomas Jensen (co-founder, SVP IR).
- David Roth, M.D., brings 25+ years oncology drug development experience; currently CMO of Syros Pharmaceuticals.
- Bylaws amended: stockholder quorum reduced from majority to 33.33% of voting power.
- Independent director annual retainer raised to $50,000; Roth received options for 23,000 shares at $1.28.
- Cullem continues as CEO and Chief Business Officer; Jensen as SVP Investor Relations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390022038536/0001213900-22-038536-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390022038536/ea162649-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-038536

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer